Poster Schedule

1:30 PM – 2:30 PM EEST

NSP-01: Update to Nursing Care Pathway for Infection risk and Prophylaxis in RRMM receiving novel therapy

1:30 PM – 2:30 PM EEST

NSP-02: Clinical Trial Enrollment at a National Cancer Institute Cancer Center in the US Mountain West

1:30 PM – 2:30 PM EEST

NSP-03: Practical Management of Patients With Relapsed/Refractory Multiple Myeloma Receiving Talquetamab, a GPRC5D×CD3 Bispecific Antibody: Experience in MonumenTAL-1

1:30 PM – 2:30 PM EEST

NSP-04: Managing Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab in Relapsed/Refractory Multiple Myeloma: Nurse-Led Experience From the MajesTEC-1 Study

1:30 PM – 2:30 PM EEST

NSP-05: Managing Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience With Teclistamab in the MajesTEC-1 Study

1:30 PM – 2:30 PM EEST

NSP-06: Scrambler Therapy for Neuropathic Pain: A Systematic Review of Evidence in Plasma Cell Disorders

1:30 PM – 2:30 PM EEST

NSP-07: A Comparison of Reach and Effectiveness of Live versus Virtual Case-Based Education for Nurses

1:30 PM – 2:30 PM EEST

NSP-08: Co-designing a pilot patient support program (PSP) for a multiple myeloma (MM) therapy prior to listing on the Pharmaceutical Benefits Scheme

1:30 PM – 2:30 PM EEST

NSP-09: Clinical validation of the Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM) in a multi-centre study

1:30 PM – 2:30 PM EEST

NSP-10: Addressing the complex care needs of the individual with Multiple Myeloma (MM) and their family: contribution of advanced practice myeloma nurses

1:30 PM – 2:30 PM EEST

NSP-11: Haematology Society of Australia & New Zealand Myeloma Specialists Practice Network (MSPN) Consensus recommendations on supportive care for patients with multiple myeloma receiving selinexor

1:30 PM – 2:30 PM EEST

NSP-12: Multiple Myeloma and Disparate Populations: The Path Forward

1:30 PM – 2:30 PM EEST

NSP-13: Multiple Myeloma: Validation of the Values and Preferences Elicitation Questionnaire- Cure and Survival Preference Scale (VPEQ-CSPS)

1:30 PM – 2:30 PM EEST

NSP-14: Project to Improve Volume of Treatment and Satisfaction (PIVOTS): Optimizing Physician and Advanced Practice Provider Workflow

1:30 PM – 2:30 PM EEST

P-001: The bone marrow stroma influences extrinsic apoptotic signaling and results in resistance to BCMA CAR-T cell induced cell death

1:30 PM – 2:30 PM EEST

P-002: Impact of Bridging Therapy (BT) on outcome of Relapsed Refractory Multiple Myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world Experience from the U.S. Myeloma CAR T Consortium

1:30 PM – 2:30 PM EEST

P-003: Clinical outcomes among multiple myeloma and lymphoma patients taking beta-blockers undergoing CAR-T therapy

1:30 PM – 2:30 PM EEST

P-004: Expansion, persistence, and characteristics of autologous, BHV-1100 ARMored memory-like NK cells infused prior to autologous stem cell transplant in MRD+, newly diagnosed multiple myeloma patients

1:30 PM – 2:30 PM EEST

P-005: Association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM)

1:30 PM – 2:30 PM EEST

P-006: sBCMA has utility for early response monitoring in the blood and is correlated with forimtamig pharmacodynamic activity, clinical response and MRD

1:30 PM – 2:30 PM EEST

P-007: Prognostic Impact of Corticosteroid and Tocilizumab Use on the Efficacy of Chimeric Antigen Receptor T-cell Therapy for Relapsed/Refractory Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-008: Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy

1:30 PM – 2:30 PM EEST

P-009: Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma

1:30 PM – 2:30 PM EEST

P-010: Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel)

1:30 PM – 2:30 PM EEST

P-011: Hematopoietic reconstitution and infections after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma are associated with pre-CAR-T bridging therapies

1:30 PM – 2:30 PM EEST

P-012: Safety and Efficacy of Standard of Care (SOC) Teclistamab (TEC) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a single center experience

1:30 PM – 2:30 PM EEST

P-013: Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy.

1:30 PM – 2:30 PM EEST

P-014: TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: PATIENTS CHARACTERISTICS FROM POST MARKETING ACCES (ACCES PRECOCE) IN FRANCE

1:30 PM – 2:30 PM EEST

P-015: A Novel CAR-T cell therapy targeting kappa myeloma antigen for the treatment of multiple myeloma

1:30 PM – 2:30 PM EEST

P-016: DISPARITIES IN ACCESS AND PRACTICE PATTERNS OF BCMA-DIRECTED T-CELL ENGAGER (TCE) THERAPIES IN MULTIPLE MYELOMA: A GLOBAL PERSPECTIVE

1:30 PM – 2:30 PM EEST

P-017: Real-World Efficacy of CAR T-Cell Therapies: A HealthTree Cure Hub’s Study of Multiple Myeloma Patients

1:30 PM – 2:30 PM EEST

P-018: Prior BCMA-directed bispecific antibody or CAR T is not associated with increased risk of early infections in patients treated with bispecific antibodies.

1:30 PM – 2:30 PM EEST

P-019: Novel combination immunotherapy for relapsed/refractory multiple myeloma (RRMM): initial Phase 1 safety run-in results for cevostamab in combination with pomalidomide and dexamethasone

1:30 PM – 2:30 PM EEST

P-020: Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance following Autologous Hematopoietic Cell Transplant (HCT) results in long-term sustained T cell activation and clonotypic expansion

1:30 PM – 2:30 PM EEST

P-021: Durable response to CAR T cell treatment is associated with the downstream triggering of native T cell immunity: a lesson learned from B cell lymphoma patients

1:30 PM – 2:30 PM EEST

P-022: DEVELOPMENT OF TROGOCYTOSIS RESISTANT CAR-NK FOR MULTIPLE MYELOMA

1:30 PM – 2:30 PM EEST

P-023: Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D × CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: Efficacy and Safety of Patient Subgroups from MonumenTAL-1

1:30 PM – 2:30 PM EEST

P-024: Early outcomes and therapy modification strategies in Multiple Myeloma patients treated with teclistamab, CD3XBCMA BITE; a single center experience.

1:30 PM – 2:30 PM EEST

P-025: Synergistic antitumor activity of the BCMA 2+1 T-cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and CELMoD agents in multiple myeloma (MM) preclinical models

1:30 PM – 2:30 PM EEST

P-026: Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma

1:30 PM – 2:30 PM EEST

P-027: Hotspot mutations in BCMA extracellular domain lead to differential susceptibility to anti-BCMA targeted immunotherapies

1:30 PM – 2:30 PM EEST

P-028: Canadian-made single domain antibody (sdAb) BCMA CAR-T cells for Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-029: Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma

1:30 PM – 2:30 PM EEST

P-030: First Results From the RedirecTT-1 Study With Teclistamab (tec) + Talquetamab (tal) Simultaneously Targeting BCMA and GPRC5D in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

1:30 PM – 2:30 PM EEST

P-031: Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy

1:30 PM – 2:30 PM EEST

P-032: Ide-cel versus standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in the modified intention to-treat (mITT) population

1:30 PM – 2:30 PM EEST

P-033: Real World Evaluation of Teclistamab in Patients with RRMM: Results from the IMF Immunotherapy Database Project

1:30 PM – 2:30 PM EEST

P-034: Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

1:30 PM – 2:30 PM EEST

P-036: REAL WORLD SINGLE CENTER EXPERIENCE OF LONG-TERM TOXICITIES WITH ANTI-BCMA CAR T-CELL THERAPY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

1:30 PM – 2:30 PM EEST

P-037: BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study

1:30 PM – 2:30 PM EEST

P-038: Impact of Absolute Lymphocyte Count at pre-apheresis and pre-lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

1:30 PM – 2:30 PM EEST

P-039: Vitamin D Deficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-040: Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis

1:30 PM – 2:30 PM EEST

P-041: Efficacy and safety of BCMA-specific CAR T cell-based therapy in relapsed/refractory multiple myeloma patients with extramedullary disease

1:30 PM – 2:30 PM EEST

P-042: Early infections in myeloma patients treated with anti-BCMA bispecific antibodies.

1:30 PM – 2:30 PM EEST

P-043: Leveraging wearable devices for remote patient monitoring facilitate earlier CRS detection following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM): Early results from an IIT

1:30 PM – 2:30 PM EEST

P-044: Evaluation of the efficacy and safety of two different linvoseltamab Phase 2 dose regimens: Results from LINKER-MM1

1:30 PM – 2:30 PM EEST

P-045: Early Treatment With Bispecific T-cell Redirectors (Teclistamab or Talquetamab) + Daratumumab in Newly Diagnosed High-risk Multiple Myeloma: An Open-label, Phase 2, Pilot Study (GEM-TECTAL)

1:30 PM – 2:30 PM EEST

P-046: Trial in Progress: Linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma

1:30 PM – 2:30 PM EEST

P-047: TRIAL IN PROGRESS: AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY OF IGM-2644 IN PARTICIPANTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

1:30 PM – 2:30 PM EEST

P-048: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS MOSTLY WITH HIGH-RISK DISEASE FEATURES

1:30 PM – 2:30 PM EEST

P-049: Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience

1:30 PM – 2:30 PM EEST

P-050: GEN3014 (HexaBody®-CD38) Versus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Design of Randomized Head-to-Head Expansion Cohort of Phase 1/2 Trial

1:30 PM – 2:30 PM EEST

P-051: Safety and efficacy of chimeric antigen receptor T cell therapy in patients with relapse or refractory multiple myeloma and hepatitis B virus-infection

1:30 PM – 2:30 PM EEST

P-052: LINKER-MM3, a Phase 3, Open-Label, Randomized Study of Linvoseltamab Versus Elotuzumab, Pomalidomide, and Dexamethasone (EPd) in Relapsed/Refractory Multiple Myeloma (RRMM)

1:30 PM – 2:30 PM EEST

P-053: Idecabtagene vicleucel (ide-cel) retreatment response was characterized by poor activation, impaired cellular expansion, and limited cytolytic activity of chimeric antigen receptor (CAR) T cells

1:30 PM – 2:30 PM EEST

P-054: Optimizing the Vk*MYC multiple myeloma model to investigate osteolytic bone lesions

1:30 PM – 2:30 PM EEST

P-055: CLINICAL FACTORS DETERMINING THE SURVIVAL OF MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE: A SINGLE-CENTER EXPERIENCE

1:30 PM – 2:30 PM EEST

P-056: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL

1:30 PM – 2:30 PM EEST

P-057: Role of the combination of FDG-PET plus Whole body MRI for staging newly diagnosed and relapsed/refractory Multiple Myeloma: a prospective trial

1:30 PM – 2:30 PM EEST

P-058: Systematic review and meta-analysis of the symptoms and treatment options of multiple myeloma in sub-Saharan African patients

1:30 PM – 2:30 PM EEST

P-059: Integrative radiomic and immunological analysis for risk classification and outcome prediction in monoclonal gammopathies

1:30 PM – 2:30 PM EEST

P-060: An effective approach using ensemble learning based on a random subspace method in laser-induced breakdown spectroscopy to diagnose blood cancer

1:30 PM – 2:30 PM EEST

P-061: Spinal involvement predicts for inferior overall survival (OS), progression free survival (PFS) and higher skeletal related events risk in Multiple Myeloma (MM) patients. A Single center experience.

1:30 PM – 2:30 PM EEST

P-062: Real-world evidence of bisphosphonates and denosumab for Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-063: Comparison of whole-body imaging in multiple myeloma with respect to lytic involvement and presence of extramedullary disease

1:30 PM – 2:30 PM EEST

P-064: COMPARISON BETWEEN MRI AND PET/CT IN THE DIAGNOSIS OF PLASMACYTOMAS AND THEIR CLINICAL AND RADIOLOGICLA FOLLOW-UP

1:30 PM – 2:30 PM EEST

P-065: WHOLE BODY LOW DOSE CT (WBLDCT), AS INITIAL IMAGING MODALITY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: EXPERIENCE FROM A TERTIARY CARE CENTER IN NORTH INDIA

1:30 PM – 2:30 PM EEST

P-066: BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma

1:30 PM – 2:30 PM EEST

P-067: Intestinal nitrogen-recycling bacteria contribute to osteolysis in Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-068: IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS

1:30 PM – 2:30 PM EEST

P-069: Liquid biopsy monitoring is more sensitive than alternative techniques in extramedullary multiple myeloma

1:30 PM – 2:30 PM EEST

P-070: Failure to Clear Circulating Tumor Cells After One Week of Daratumumab, Bortezomib and Dexamethasone is Associated with a Reduced Progression-Free Survival for Myeloma Patients

1:30 PM – 2:30 PM EEST

P-071: Hevylite in the multiple myeloma patient pathway

1:30 PM – 2:30 PM EEST

P-072: Multiple Myeloma Patient Perceptions of Minimal Residual Disease Testing

1:30 PM – 2:30 PM EEST

P-073: Modelling multiple myeloma using best clinical response to treatment to predict overall survival

1:30 PM – 2:30 PM EEST

P-074: Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients

1:30 PM – 2:30 PM EEST

P-075: Real-world evidence on prognostic value of minimal residual disease in multiple myeloma: Czech experience

1:30 PM – 2:30 PM EEST

P-076: The impact of heterogeneous disease distribution on MRD detection in patients with relapsed multiple myeloma

1:30 PM – 2:30 PM EEST

P-077: High Sensitivity MRD Enumeration Using Combined Size Exclusion Isolation and Immunophenotyping

1:30 PM – 2:30 PM EEST

P-078: MRDeep Study: Measurable Residual Disease rates in patients with Multiple Myeloma who achieved complete response in 2nd or 3rd lines of treatment.

1:30 PM – 2:30 PM EEST

P-079: Impact of treatment effect on measurable residual disease (MRD) and progression-free survival (PFS): an aggregate data analysis from randomized clinical trials in multiple myeloma (MM)

1:30 PM – 2:30 PM EEST

P-080: Clinical implication of MRD measurement by DuraClone in patients with transplant-eligible, real-world-based study, CAREMM-2104

1:30 PM – 2:30 PM EEST

P-081: Sensitive detection of M-proteins and FLC in blood for diagnosis and monitoring of multiple myeloma

1:30 PM – 2:30 PM EEST

P-082: Will survival improve by treating multiple myeloma patients at MRD relapse? The REMNANT study

1:30 PM – 2:30 PM EEST

P-083: The role of minimal residual disease evaluation for patients with multiple myeloma

1:30 PM – 2:30 PM EEST

P-084: Use of Peripheral Blood for MRD Assessment During Maintenance Therapy: UTSW Experience

1:30 PM – 2:30 PM EEST

P-085: The Use of Clonotypic Mass Spectrometry for Post-AHCT Blood-Based Measurable Residual Disease Monitoring in Patients with Light Chain Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-086: Patient and Haematologist Perspectives of Minimal Residual Disease Testing in Myeloma

1:30 PM – 2:30 PM EEST

P-087: Characterization of minimal residual disease (MRD) in patients with relapsed/refractory multiple myeloma treated with elranatamab: Analysis of MagnetisMM-3

1:30 PM – 2:30 PM EEST

P-088: High throughput MGUS monitoring program to support incidental MGUS (iMGUS) detection in the community.

1:30 PM – 2:30 PM EEST

P-089: Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma

1:30 PM – 2:30 PM EEST

P-090: CLINICAL CHARACTERISTICS AND RISK OF PROGRESSION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE: LONG-TERM EXPERIENCE IN A SINGLE TERTIARY HOSPITAL.

1:30 PM – 2:30 PM EEST

P-091: Senescence features in pre-malignant plasma cells and their microenvironment are associated with stable disease in MGUS and SMM

1:30 PM – 2:30 PM EEST

P-092: High Serum Free Light Chains levels in African Ancestry population screened for Monoclonal Gammopathy: implication for definition of FLC Reference Range Accounting for Renal Function and Race

1:30 PM – 2:30 PM EEST

P-093: Solitary Plasmacytoma: Single institution experience and systematic review and meta-analysis of clinical outcomes

1:30 PM – 2:30 PM EEST

P-094: CHARACTERISING RISK AND BIOLOGY OF SMOULDERING MYELOMA FOR EARLY DETECTION OF SYMPTOMATIC MYELOMA: DATA FROM THE UK COSMOS STUDY

1:30 PM – 2:30 PM EEST

P-095: Evolving M-spike and Risk of Progression in Smoldering Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-096: Real world evidence of suboptimal humoral and cellular immune response to vaccination in ostensibly asymptomatic patients with precursor stage of multiple myeloma

1:30 PM – 2:30 PM EEST

P-097: Single-Cell RNA Sequencing of Circulating Tumor Cells in Precursor Myeloma Patients Reveals Early Mechanisms of Disease Dissemination

1:30 PM – 2:30 PM EEST

P-098: Prevalence of Metabolic Comorbidities and Viral Co-infections in Monoclonal Gammopathy: A Retrospective Analysis

1:30 PM – 2:30 PM EEST

P-099: Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-100: Prevalence of Monoclonal Gammopathies in adult Uruguayan population

1:30 PM – 2:30 PM EEST

P-101: Single-cell RNA sequencing of 1.3 million plasma cells from patients with MGUS and SMM

1:30 PM – 2:30 PM EEST

P-102: Thrombotic Significance in Plasma Cell Disorders: Do associated clonal hematopoiesis of indeterminate potential (CHIP) mutations increase the risk?

1:30 PM – 2:30 PM EEST

P-103: ALBUMIN: GLOBULIN REVERSAL AS A SCREENING TOOL FOR MGUS (TARGETED SCREENING) IN HOSPITALIZED SETTING

1:30 PM – 2:30 PM EEST

P-104: Prevalence of MGUS in rural Indian population: Results of SIMPLe (IMAGe-002) study

1:30 PM – 2:30 PM EEST

P-105: Multiple Myeloma Therapy in Tawam Hospital. First Report from United Arab Emirates

1:30 PM – 2:30 PM EEST

P-106: Clinical outcomes of older patients aged 80 and over with newly diagnosed multiple myeloma

1:30 PM – 2:30 PM EEST

P-107: The second revision of international staging system (R2-ISS) in newly diagnosed multiple myeloma patients: RWE settings

1:30 PM – 2:30 PM EEST

P-108: Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain. CARINAE Study.

1:30 PM – 2:30 PM EEST

P-109: Carfilzomib-Lenalidomide-Dexamethasone Vs. Lenalidomide-Dexamethasone in Non-Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: The EMN20 Trial

1:30 PM – 2:30 PM EEST

P-110: Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: Final overall survival analysis from the TOURMALINE-MM4 study

1:30 PM – 2:30 PM EEST

P-111: Overall survival trends in young (<55 years) transplant-inaccessible multiple myeloma patients treated at a safety net hospital system

1:30 PM – 2:30 PM EEST

P-112: Determining the impact of multimorbidity in older patients initiating treatment for newly-diagnosed multiple myeloma using artificial intelligence/machine learning methods

1:30 PM – 2:30 PM EEST

P-113: Clinical Consensus on First-Line (1L) Treatments for Transplant-Ineligible (TIE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Delphi Panel of US Hematologists and Oncologists

1:30 PM – 2:30 PM EEST

P-114: In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: Updated subgroup analysis from the fully accrued US MM-6 study

1:30 PM – 2:30 PM EEST

P-115: Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: A Chart Review Study

1:30 PM – 2:30 PM EEST

P-116: The simplified frailty index (S-FI) identifies a less vulnerable population of frail patients than patients who are defined frail using the International Myeloma working Group Frailty index (IMWG-FI)

1:30 PM – 2:30 PM EEST

P-117: A prognostic score based on age, eGFR (CKD-EPI), performance status and ultra-high-risk disease outperforms R2-ISS for elderly myeloma patients: An analysis of the Greek Myeloma Study Group Registry

1:30 PM – 2:30 PM EEST

P-118: Machine learning assisted risk stratification of newly diagnosed multiple myeloma with respect to the VRd treatment

1:30 PM – 2:30 PM EEST

P-119: The role of lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma in clinical practice: comparison with bortezomib-based therapy

1:30 PM – 2:30 PM EEST

P-120: Impact of exclusion from clinical trials in non-candidate transplant patients with newly diagnosed multiple myeloma

1:30 PM – 2:30 PM EEST

P-121: Real World Outcomes of Undocumented Multiple Myeloma Patients: A Safety Net Hospital Experience

1:30 PM – 2:30 PM EEST

P-122: Ocular Adverse Events and Functional Impact in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients Treated with Belantamab Mafodotin, Lenalidomide and Dexamethasone in BelaRd Trial

1:30 PM – 2:30 PM EEST

P-123: Safety and Clinical Activity of Belantamab Mafodotin plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: The Phase 1/2 BelaRd study

1:30 PM – 2:30 PM EEST

P-124: Therapeutic efficacy of ixazomib-based regimen in frail patients with newly diagnosed multiple myeloma based on the dynamic assessment of frailty

1:30 PM – 2:30 PM EEST

P-125: Ixazomib versus Lenalidomide or Ixazomib and Lenalidomide combination as maintenance regimen for transplant-ineligible multiple myeloma: update of a multi-center prospective study in China

1:30 PM – 2:30 PM EEST

P-126: Adding value of serum-free light chain in assessing response and progression in multiple myeloma with measurable disease.

1:30 PM – 2:30 PM EEST

P-127: Bone marrow plasmacytosis >5% at time of autologous transplant influences survival outcomes in patients with standard risk cytogenetics

1:30 PM – 2:30 PM EEST

P-128: DARATUMUMAB- VTD VS VTD. PERI-TRANSPLANT EVALUATION.

1:30 PM – 2:30 PM EEST

P-129: REAL WOLRD EVIDENCE OF PROGNOSTIC IMPACT OF t(14;16) TRANSLOCATION IN MULTIPLE MYELOMA: A REPORT OF THE MYELOMA TRIVENETO WORKING GROUP

1:30 PM – 2:30 PM EEST

P-130: Retrospective assessment of outcomes with autologous bone marrow transplant in multiple myeloma - Real world data of 23 years.

1:30 PM – 2:30 PM EEST

P-131: Daratumumab (dara) as maintenance therapy after autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): Results of a phase 2 study

1:30 PM – 2:30 PM EEST

P-132: Post-induction Undetectable Flow Minimal Residual Disease ameliorates the high risk determined by FISH among Newly Diagnosed Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-133: Validation of two International Myeloma Staging Systems: Second Revision of ISS and Mayo Additive Staging Sytems (MASS) in an external cohort of Ankara University

1:30 PM – 2:30 PM EEST

P-134: Clonal Isotype Switch predicts long-term survival in Multiple Myeloma after Autologous Stem Cell Transplantation.

1:30 PM – 2:30 PM EEST

P-135: Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)

1:30 PM – 2:30 PM EEST

P-136: Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

1:30 PM – 2:30 PM EEST

P-137: A phase 3, two-stage, randomized study of iberdomide maintenance versus lenalidomide maintenance post autologous stem cell transplantation in newly diagnosed multiple myeloma: EXCALIBER-Maintenance

1:30 PM – 2:30 PM EEST

P-138: Online CME improves clinical decision-making in the management of patients with multiple myeloma

1:30 PM – 2:30 PM EEST

P-139: Impact of Melphalan Staggered Dosing Prior to Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Patients

1:30 PM – 2:30 PM EEST

P-140: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY

1:30 PM – 2:30 PM EEST

P-141: Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients

1:30 PM – 2:30 PM EEST

P-142: Stem cell collection after isatuximab or elotuzumab plus lenalidomide, bortezomib and dexamethasone in transplant-eligible multiple myeloma: single center data from the GMMG-HD6 and -HD7 trials

1:30 PM – 2:30 PM EEST

P-143: Treatment access among Black and White older adults with multiple myeloma: A SEER-Medicare analysis

1:30 PM – 2:30 PM EEST

P-144: Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

1:30 PM – 2:30 PM EEST

P-145: Early M protein immune reconstitution is a good prognostic marker for patients with high-risk cytogenetic multiple myeloma after autologous hematopoietic stem cell transplantation

1:30 PM – 2:30 PM EEST

P-146: MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma

1:30 PM – 2:30 PM EEST

P-147: Obtaining M protein immune reconstitution as soon as possible after Tandem autologous hematopoietic stem cell transplantation improves the prognosis of patients with Newly diagnosis multiple myeloma

1:30 PM – 2:30 PM EEST

P-148: On-demand plerixafor added to high-dose cyclophosphamide and Pegfilgrastim in the mobilization of patients with multiple myeloma: High effectiveness and affordable cost

1:30 PM – 2:30 PM EEST

P-149: Follw-up of transplant-eligible multiple myeloma received Busulfan-based conditioing versus high-dose melphalan

1:30 PM – 2:30 PM EEST

P-150: Autologous stem cell transplantation (ASCT) is still crucial for multiple myeloma (MM) patients with undetectable minimal residual disease after induction treatment

1:30 PM – 2:30 PM EEST

P-151: Demographic and Clinical Characteristics of Multiple Myeloma Patients in a Tertiary Cancer institute of India

1:30 PM – 2:30 PM EEST

P-152: Attrition Rates in Multiple Myeloma and factors influencing patient dropouts at a tertiary referral center in India.

1:30 PM – 2:30 PM EEST

P-153: Maintenance therapy with carfilzomib, pomalidomide and dexamethasone (KPd) in high-risk myeloma patients (pts): A Phase 2 study with a safety run-in

1:30 PM – 2:30 PM EEST

P-154: Biomarker utility of circRNAs in multiple myeloma: The exemplary cases of ciRS-7 and circCCT3 as surrogate prognostic molecular biomarkers combined with the R-ISS staging system

1:30 PM – 2:30 PM EEST

P-155: Comparative Analysis of Outcomes in Patients with CRAB versus SLiM Criteria at Diagnosis of Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-156: OUTCOMES OF A BORTEZOMIB-BASED INDUCTION REGIMEN (SEQUENTIAL OR UPFRONT TRIPLE ASSOCIATION WITH LENALIDOMIDE) IN TRANPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

1:30 PM – 2:30 PM EEST

P-157: How public policies have improved the overall survival of transplant eligible newly diagnosed multiple myeloma patients in the Chilean public health system

1:30 PM – 2:30 PM EEST

P-158: EXPERIENCE AT SON ESPASES UNIVERSITARY HOSPITAL WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (D-VRd) AS FIRST LINE TREATMENT IN MULTIPLE MYELOMA

1:30 PM – 2:30 PM EEST

P-159: Lenalidomide maintenance in R2-ISS stratified multiple myeloma patients - real world evidence

1:30 PM – 2:30 PM EEST

P-160: Real World Data on Demographics, Management and Outcome of Ultra High Risk Myeloma - Experience from a Tertiary Care Centre

1:30 PM – 2:30 PM EEST

P-161: IMPACT OF INDUCTION TREATMENT ON THE SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA CANDIDATES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION. EXPERIENCE OF A CENTER.

1:30 PM – 2:30 PM EEST

P-162: Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma

1:30 PM – 2:30 PM EEST

P-163: Treatment Patterns and Outcomes in Newly Diagnosed Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-164: Reduction in Disease Symptoms/Impacts After Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Treatment for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma (GRIFFIN Study)

1:30 PM – 2:30 PM EEST

P-165: Incidence, risk factors and impact of supraventricular tachycardia (SVT) with high dose therapy melphalan among myeloma patients undergoing autologous stem cell transplant (HDT/ASCT)

1:30 PM – 2:30 PM EEST

P-166: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) vs Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma

1:30 PM – 2:30 PM EEST

P-167: Serum BCMA levels evaluated by Elecsys sBCMA assay at diagnosis have prognostic value in patients with multiple myeloma

1:30 PM – 2:30 PM EEST

P-168: Solo G-CSF versus chemotherapy-based stem cell mobilization in Hungarian transplantation-eligible patients

1:30 PM – 2:30 PM EEST

P-169: CLINICAL FEATURES AND OUTCOME PATTERNS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO ARE CANDIDATE FOR TRANSPLANT: A SINGLE CENTER EXPERIENCE IN PARAGUAY

1:30 PM – 2:30 PM EEST

P-170: Stem cell mobilization and autologous stem cell transplantation after induction with bendamustine, prednisone and bortezomib (BPV) in 135 untreated myeloma patients with variable renal function

1:30 PM – 2:30 PM EEST

P-171: The changing landscape of peri-transplant adverse events with HDT/ASCT and the impact on long term outcomes for myeloma patients

1:30 PM – 2:30 PM EEST

P-172: AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA – A SINGLE CENTER EXPERIENCE FROM INDIA

1:30 PM – 2:30 PM EEST

P-173: Development and validation of an individualized and weighted myeloma prognostic score system (MPSS) in patients with newly diagnosed multiple myeloma

1:30 PM – 2:30 PM EEST

P-174: Early relapse within 18 months (ER18) is a powerful dynamic predictor for prognosis and could revise static risk distribution in patients with new-diagnosed multiple myeloma